Synthace Ltd., the bioengineering company leveraging multidimensional experimentation and Synthace, an unambiguous language to describe process workflows to transform the productivity of biological systems, announced today that it has entered into a new relationship with MSD (known as Merck & Co., Inc., Kenilworth, NJ, USA, in the United States and Canada), that builds on a previous agreement initiated in 2014. The collaboration will utilize Synthace’s high throughput methods and tools to develop a biomanufacturing platform for a number of undisclosed molecules.
“We are delighted to extend our relationship with MSD, a recognized leader in bioprocess innovation within the pharma industry,” stated Synthace chief executive officer Tim Fell. “This collaboration is focused on the rapid development of a high productivity, low cost of goods biomanufacturing process through the use of our next-generation approach to simultaneous genetic and process optimization.”
About Synthace
Synthace engineers biology for applications across health, food, energy and manufacturing. Combining computation, biology and automation the company rapidly develops robust, high-yielding bioprocesses to make bio-based products with strategic partners. Central to Synthace’s technology is the Synthace platform, which brings quality by design and design for manufacturing to biological research and development. Learn more at www.synthace.com.
